Compare Apple Inc (AAPL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Twist Bioscience Corp — how do they compare? Apple Inc trades at $308.6 (market cap $4.56T), while Twist Bioscience Corp trades at $89.86 (market cap $5.67B). The key difference: Apple Inc is far larger — about 804.2× Twist Bioscience Corp's market cap, and Apple Inc pays a 0.35% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| AAPL | TWST | |
|---|---|---|
Market Cap | $4.56T | $5.67B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $102.88 |
52-Week Low | $202.38 | $24.16 |
Enterprise Value | $4.58T | $5.59B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $311.75, down 0.29% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats and a 62.73% analyst buy rating support the stock, which is near the consensus price target of $329.62. Revenue growth accelerated to $416.16B in 2025, with net income reaching $112.01B, though valuation multiples like a P/E of 37.61 are elevated. Positive news includes leadership in smartphone shipments and AI potential from 2.5 billion active devices.
The outlook remains positive given earnings momentum and institutional support, but risks include high valuation, potential Q2 2026 earnings miss concerns, and regulatory scrutiny. Upside is capped near-term by resistance at $316, while support lies at $308. The stock offers growth exposure with dividend income, yet investors face volatility from tech sector rotation and macroeconomic pressures.
Twist Bioscience (TWST) trades at $91.03, down 8.27% in the past day, amid mixed earnings performance. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Revenue growth remains robust, rising to $377 million in 2025, but profitability challenges persist with a net income margin of -19.85%. Recent news highlights AI-driven drug discovery collaborations and insider selling activity.
The outlook is cautiously optimistic given analyst consensus favoring buys (76.93%) and a price target near current levels. Key risks include sustained cash burn, competitive pressures in synthetic biology, and execution on path to profitability. Upside hinges on revenue acceleration and margin improvement from new product launches and AI partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
